CCND1: G1/S-specific cyclin-D1
Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on CCND1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Briciclib | Phase 2 | Traws Pharma, Inc. | Small molecule | InhibitorG1/S-specific cyclin D1 inhibitor | 0 |
- Breast cancer0.65
- Breast carcinoma0.59
- Prostate carcinoma0.54
- Plasma cell myeloma0.54
- Neurodegenerative disease0.53
- Type 2 diabetes mellitus0.53
- AL amyloidosis0.51
- Breast neoplasm0.50
- Diabetes mellitus0.49
- Neoplasm0.45
- Von Hippel-Lindau disease0.42
- Endometrial cancer0.42
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3610, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P24385, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets